Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Matteo Della Porta(University of Milan), David Valcárcel(Vall d'Hebron Hospital Universitari), Veronika Pozharskaya(Bristol-Myers Squibb (United States)), Jake Shortt(The University of Melbourne), Amer M. Zeidan(Yale Cancer Center), Yinzhi Lai(Bristol-Myers Squibb (United States)), Uwe Platzbecker(National Center for Tumor Diseases), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Pierre Fenaux(Assistance Publique – Hôpitaux de Paris), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Shelonitda Rose(Universidad San Carlos), Rami S. Komrokji(Moffitt Cancer Center), Ana Carolina Giuseppi(Bristol-Myers Squibb (United States)), Aylin Yücel(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655